NRX Pharmaceuticals (NRXP) Gross Margin (2025 - 2026)

NRX Pharmaceuticals (NRXP) posted quarterly Gross Margin of 40.92% for Q1 2026, down 28.73% quarter-over-quarter from 57.41% in Q4 2025.

NRX Pharmaceuticals (NRXP) Gross Margin (2025 - 2026) Analysis & Trends

NRX Pharmaceuticals (NRXP) has reported Gross Margin for 2 consecutive years, with 40.92% the latest figure, recorded in Q1 2026.

In Q1 2026, Gross Margin changed N/A year-over-year to 40.92%; the TTM figure through Mar 2026 stood at 48.97% (changed N/A YoY), while the FY2025 annual figure was 57.92%, changed N/A from the prior year.
Gross Margin eased to 40.92% in Q1 2026 per NRXP's latest filing, from 57.41% in the prior quarter.
Across five years, Gross Margin topped out at 57.41% in Q4 2025 and bottomed at 40.92% in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Vertex Pharmaceuticals	139.66 Bn	131.81 Bn	2.84 Bn	85.33%
2	Regeneron Pharmaceuticals	86.52 Bn	78.52 Bn	3.93 Bn	91.59%
3	Argenx Se	65.30 Bn	60.11 Bn	1.37 Bn	90.43%
4	Moderna	59.18 Bn	54.04 Bn	52.00 Mn	35.86%
5	BeOne Medicines	42.08 Bn	36.98 Bn	1.53 Bn	89.76%
6	Alnylam Pharmaceuticals	31.77 Bn	28.46 Bn	992.69 Mn	76.90%
7	BioNTech SE	28.13 Bn	9.74 Bn	668.28 Mn	63.27%
8	Insmed	27.51 Bn	26.35 Bn	358.27 Mn	84.20%
9	Royalty Pharma	27.16 Bn	26.32 Bn	-	-
10	NRX Pharmaceuticals	132.83 Mn	106.13 Mn	426,000.00	38.69%

Download Data